Eusol Biotech Co.,Ltd. (TPEX:6652)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
1.960
0.00 (0.00%)
Apr 9, 2026, 2:59 PM CST
Market Cap268.52M -75.3%
Revenue (ttm)2.08M
Net Income-40.42M
EPS-0.30
Shares Out137.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,488,893
Average Volume1,149,797
Open2.250
Previous Close1.960
Day's Range1.870 - 2.280
52-Week Range1.870 - 10.200
Beta-0.08
RSI21.53
Earnings DateMay 7, 2026

About Eusol Biotech

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Employees 39
Stock Exchange Taipei Exchange
Ticker Symbol 6652
Full Company Profile

Financial Performance

Financial Statements